Ling Tong

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineNeuroscienceImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “An in vivo Biomarker to Characterize Ototoxic Compounds and Novel Protective Therapeutics”.

An in vivo Biomarker to Characterize Ototoxic Compounds and Novel Protective Therapeutics

Frontiers in Molecular Neuroscience(2022)10.3389/fnmol.2022.944846

N/A

0DataRank · unranked

3 citations

Van A. Redila, Patricia Wu, Ling Tong, Alyssa A. Webster, Julian A. Simon +3 more

An in vivo biomarker to characterize ototoxic compounds and novel protective therapeutics

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.05.31.493913

N/A

0DataRank · unranked

0 citations

Van A. Redila, Patricia Wu, Ling Tong, Alyssa A. Webster, Julian A. Simon +3 more

An HIV fusion-inhibitory lipopeptide provides robust post-exposure prophylaxis and prevents viral reservoir seeding in macaques

Cell Reports(2025)10.1016/j.celrep.2025.116228

N/A

0DataRank · unranked

1 citations

Yuanmei Zhu, Chenbo Yang, Xiaosheng Liu, Rui Hou, Wei Wang +11 more